Vertex Pharmaceuticals Incorporated (FRA:VX1)
330.45
-2.25 (-0.68%)
At close: Sep 30, 2025
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.96B USD in the quarter ending June 30, 2025, with 12.06% growth. This brings the company's revenue in the last twelve months to $11.42B, up 10.46% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.42B
Revenue Growth
+10.46%
P/S Ratio
8.89
Revenue / Employee
$1.87M
Employees
6,100
Market Cap
86.39B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 78.30B |
Deutsche Telekom AG | 120.55B |
Allianz SE | 109.02B |
Rheinmetall AG | 10.67B |
Siemens Energy AG | 38.39B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
Deutsche Bank Aktiengesellschaft | 30.07B |
Vertex Pharmaceuticals News
- 12 days ago - Vertex Pharmaceuticals Secures Italian Reimbursement Agreement For Gene-Edited Therapy CASGEVY - Nasdaq
- 12 days ago - Vertex Pharmaceuticals (VRTX) Secures Italian Reimbursement for Gene-Edited Therapy - GuruFocus
- 12 days ago - Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy - Business Wire
- 14 days ago - This ETF Holds Stocks Insiders Want to Own - Nasdaq
- 15 days ago - 1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals - The Motley Fool
- 17 days ago - Vertex Pharmaceuticals: Buying The CF Fortress For The Journavx Optionality - Seeking Alpha
- 19 days ago - Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years - Benzinga
- 19 days ago - Evercore ISI Group Lowers Price Target for Vertex Pharmaceuticals (VRTX) | VRTX Stock News - GuruFocus